Cue Biopharma (CUE) Research & Development (2017 - 2025)
Cue Biopharma (CUE) posted Research & Development of $16.5 million for Q4 2025, up 247.75% sequentially from $4.8 million in Q3 2025, and up 130.12% YoY from $7.2 million in Q4 2024.
Cue Biopharma (CUE) Research & Development (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Research & Development for 9 years, with the latest figure at $16.5 million in Q4 2025.
- Quarterly Research & Development rose 130.12% year-over-year to $16.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $37.7 million (up 3.99% YoY) and the FY2025 annual result came in at $37.7 million, up 3.99% from the prior year.
- Research & Development advanced to $16.5 million in Q4 2025 per CUE's latest filing, from $4.8 million in the prior quarter.
- Over five years, Research & Development peaked at $16.5 million in Q4 2025 and troughed at $4.8 million in Q3 2025.
- A 5-year average of $9.7 million and a median of $9.7 million in 2021 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 130.12% in 2025, down 49.32% in 2025.
- Over 5 years, Research & Development stood at $11.5 million in 2021, then fell by 1.47% to $11.3 million in 2022, then dropped by 3.93% to $10.9 million in 2023, then slumped by 34.01% to $7.2 million in 2024, then jumped by 130.12% to $16.5 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $16.5 million, $4.8 million, and $7.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 49.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.53 Mn |
| Sep 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 7.91 Mn |
| Mar 31, 2025 | 8.55 Mn |
| Dec 31, 2024 | 7.18 Mn |
| Sep 30, 2024 | 9.38 Mn |
| Jun 30, 2024 | 9.53 Mn |
| Mar 31, 2024 | 10.20 Mn |
| Dec 31, 2023 | 10.89 Mn |
| Sep 30, 2023 | 9.87 Mn |
| Jun 30, 2023 | 10.65 Mn |
| Mar 31, 2023 | 9.39 Mn |
| Dec 31, 2022 | 11.33 Mn |
| Sep 30, 2022 | 7.57 Mn |
| Jun 30, 2022 | 9.59 Mn |
| Mar 31, 2022 | 10.08 Mn |
| Dec 31, 2021 | 11.50 Mn |
| Sep 30, 2021 | 11.29 Mn |
| Jun 30, 2021 | 8.76 Mn |
| Mar 31, 2021 | 9.82 Mn |